Navigation Links
Sinovac to Present at 2010 UBS Global Specialty Pharmaceuticals Conference

BEIJING, May 24 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading China-based vaccine manufacturer, announced today that Mr. Weidong Yin, Chairman, President & CEO, will present at the 2010 UBS Global Specialty Pharmaceuticals Conference, which is being held June 2-3, 2010 in London, England. Sinovac's presentation is scheduled for Wednesday, June 2, 2010 at 10 a.m. BST/5 a.m. Eastern Time.

A live webcast of the presentation will be available online on the Investor Relations Home page of the Sinovac's corporate Web site at .

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's vaccine products include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and B), and Anflu(R) (influenza). Panflu (TM), Sinovac's pandemic influenza vaccine (H5N1), has already been approved for government stockpiling. Sinovac is developing vaccines for enterovirus 71, universal pandemic influenza, Japanese encephalitis vaccine, and human rabies vaccine. Its wholly owned subsidiary, Tangshan Yian, is conducting field trials for independently developed inactivated animal rabies vaccines.

    For more information, please contact:

     Chris Lee
     Sinovac Biotech Ltd.
     Tel:   +86-10-8289-0088 x9659
     Fax:   +86-10-6296-6910

     Amy Glynn/ Stephanie Carrington
     The Ruth Group
     Tel:   +1-646-536-7023/7017

     Janine McCargo
     The Ruth Group
     Tel:   +1-646-536-7033

SOURCE Sinovac Biotech Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Sinovac Reports Unaudited First Quarter 2010 Financial Results
2. Sinovac to Host Conference Call to Report First Quarter 2010 Financial Results
3. Sinovac Announces Upsizing and Pricing of Common Share Offering
4. Sinovac Files Clinical Trial Application with SFDA for Vaccine Against Hand, Foot, and Mouth Disease
5. Sinovacs CEO Weidong Yin Presented with Annual Innovation Award by China Central Television
6. Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities
7. Sinovac Reports Unaudited Third Quarter 2009 Financial Results
8. Sinovac Obtains Third H1N1 Vaccine Order from Chinese Central Government
9. Sinovac Receives Certificate of Approval to Distribute Panflu (H5N1) Vaccine in Hong Kong
10. Sinovac to Present at 2009 UBS Global Life Sciences Conference
11. Sinovac Obtains Lot Release Certificate for Its First Batch of H1N1 Vaccine
Post Your Comments:
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Ky. , June 23, 2016 ... two Phase 1 clinical trials of its complement ... placebo-controlled, single and multiple ascending dose studies designed ... pharmacodynamics (PD) of subcutaneous injection in healthy adult ... subcutaneously (SC) either as a single dose (ranging ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance Associates® Inc. (RCA), ... free webinar on Performing Quality Investigations: Getting to Root Cause. ... no charge. , Incomplete investigations are still a major concern to the Regulatory ...
Breaking Biology Technology:
(Date:5/12/2016)... 12, 2016 , a brand ... overview results from the Q1 wave of its quarterly ... was consumers, receptivity to a program where they would ... health insurance company. "We were surprised to ... Michael LaColla , CEO of Troubadour Research, "primarily ...
(Date:4/28/2016)... India , April 28, 2016 ... Infosys (NYSE: INFY ), and Samsung SDS, a ... that will provide end customers with a more secure, ... services.      (Logo: ) , ... services, but it also plays a fundamental part in enabling ...
(Date:4/26/2016)... Research and Markets has announced ... 2016-2020"  report to their offering.  , ,     (Logo: ... analysts forecast the global multimodal biometrics market to ... period 2016-2020.  Multimodal biometrics is being ... the healthcare, BFSI, transportation, automotive, and government for ...
Breaking Biology News(10 mins):